A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder

International Clinical Psychopharmacology

Volumn 22, Issue 6, 2007, Pages 338-347

  Septien Velez, Lucia ^a   Pitrosky, Bruno ^a,c   Padmanabhan, Sudharshan Krishna ^b   Germain, Jean Michel ^a   Tourian, Karen A ^b  

^a Clinical Research and Development   (France)

^b PFIZER INC   (United States)

^c Neuroscience Department   (France)

Author keywords

Antidepressant; Desvenlafaxine; Major depressive disorder

Indexed keywords

DESVENLAFAXINE;

ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; HAMILTON SCALE; HUMAN; IMPOTENCE; LEUKOPENIA; MAJOR DEPRESSION; NAUSEA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUICIDAL IDEATION; SWEATING; TACHYCARDIA; VISUAL ANALOG SCALE; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; SEX FACTORS; SWEATING; TREATMENT OUTCOME;

EID: 34948830614     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3281e2c84b     Document Type: Article

References (20)

1. Bair MJ, Robinson RL, Katon W, Kroenke K (2003). Depression and pain comorbidity: a literature review. Arch Intern Med 163:2433-2445.
2. Bradley RH, Barkin RL, Jerome J, DeYoung K, Dodge CW (2003). Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 10:318-323.
3. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF (2005). Duloxetine 60mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 39:43-53.
4. Danjou P, Hackett D (1995). Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 10:15-20.
5. DeMartinis NA, Yeung PP, Entsuah R, Manley AL (2006). Efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry (in press).
6. Greden JF (2003). Physical symptoms of depression: unmet needs. J Clin Psychiatry 64:5-11.
7. Kupfer DJ (1991). Long-term treatment of depression. J Clin Psychiatry 52 (Suppl 5):28-34.
8. Montgomery SA, Ashberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389
9. Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH (2004). Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 55:296-300.
10. Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV (2002). Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36:106-132.
11. Nierenberg AA, Wright EC (1999). Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 60 (Suppl 22):7-11.
12. Rudolph RL, Derivan AT (1996). The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 16:54S-59S.
13. Shilling A, Young-Sciame R, Leung L. Comparison of inhibitory effects of desvenlafaxine succinate, venlafaxine, SS duloxetine, paroxetine, sertraline and bupropion on human cytochrome P450 activities. Poster presented at: International Society for the Study of Xenobiotics, October 25-27, 2005; Maui, HI.
14. Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J (1999). An international study of the relation between somatic symptoms and depression. N Engl J Med 341:1329-1335.
15. Stahl SM (1999). Why settle for silver, when you can go for gold? Response vs. recovery as the goal of antidepressant therapy. J Clin Psychiatry 60:213-214.
16. Stahl SM (2002). Does depression hurt? J Clin Psychiatry 63:273-274.
17. Thase ME, Entsuah AR, Rudolph RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241.
18. Trivedi MH (2004). The link between depression and physical symptoms. Prim Care Companion J Clin Psychiatry 6:12-16.
19. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28-40.
20. Westanmo AD, Gayken J, Haight R (2005). Duloxetine: a balanced and selective norepinephrine and serotonin-reuptake inhibitor. Am J Health Syst Pharm 62:2481-2490.